← boardnext 2026-09next 2026-11
ALKS
Alkermes, Inc.distress 0/10 · well-funded / low risk$52.450%today-5% from 52w high
Lead: Narcolepsy Type 1
Revenue
$393M
Liquidity
$577M
Runway
—
Shares 1y
+1%
Price & events
+54.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
+1.0%
1W
+9.1%
1M
+54.7%
3M
+56.1%
6M
+92.9%
1Y
+109.8%
2Y
+114.3%
5Y
+165.7%
All
Overview
- Market Cap
- $8.74B
- Enterprise Value
- $9.87B
- Volume
- 56.41K
- 52 Week Range
- $26.13 – $55.22
- Total Shares
- 166.68M
- Float Shares
- 154.05M
- Short %
- 14.56%
- % Held by Insiders
- 1.43%
- % Held by Institutions
- 110.67%
- RVOL
- 0.02x
- Beta
- 0.29
Pipeline stages · 2 programs
OLZ/SAM
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ALKS 2680, 4mg, 6mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 7 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-11-15 | Phase 3 | OLZ/SAM, Olanzapine | Schizophrenia, Bipolar I Disorder | — | recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | ALKS 2680fast track | Idiopathic Hypersomnia | — | recruiting |
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | ALKS 2680 Dose 1, ALKS 2680 Dose 2fast track | Narcolepsy Type 1 | — | recruiting |
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3fast track | Narcolepsy Type 2 | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | ALKS 2680 Dose 1, ALKS 2680 Dose 2fast track | Narcolepsy Type 1 | — | recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | OLZ/SAM | Bipolar I Disorder, Schizophrenia | — | enrolling by invitation |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 2/3 | ALKS 2680, 4mg, 6mgfast track | Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | — | recruiting |
Catalyst news & presentations · 13
- end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)LUMRYZ · Supplemental New Drug Application filing with FDA.SEC 8-K
- 2026-07-28Estimated 45%earningsEarningsEarnings releaseyahoo
- first quarter of 2026trial initiationsecondaryPhase 3alixorexton · Plan to initiate global Phase 3 program for alixorexton.SEC 8-K
- 2026-02-12partnershipEntry into $1.525B term loan credit facilitiesSEC 8-K
- 2026-02-12partnershipTermination of bridge credit agreementSEC 8-K
- 2026-02-12partnershipAcquisition of Avadel Pharmaceuticals completedSEC 8-K
- January 13, 2026conferencedata presentationsecondaryCorporate presentation at J.P. Morgan Healthcare ConferenceSEC 8-K
- H2 2025readoutPhase 2ALKS 2680 · Phase 2 data from Vibrance-1 and Vibrance-2 studiesSEC 8-K
- this yeartrial initiationsecondaryPhase 1ALKS 7290 · First-in-human studies planned for 2025.SEC 8-K
- 2025trial initiationsecondaryadditional orexin 2 receptor agonist molecules · Additional orexin 2 receptor agonist molecules expected to enter clinicSEC 8-K
- 2025-09-09partnershipVIVITROL · Authorized generic supply agreement with Amneal for VIVITROL.SEC 8-K
- Sept. 5-10, 2025conferencedata presentationsecondaryPhase 2alixorexton · Detailed results from Vibrance-1 Phase 2 study to be presented at World Sleep Congress.SEC 8-K
- H1 2025trial initiationsecondaryPhase 2ALKS 2680 · Initiation of Phase 2 study in idiopathic hypersomniaSEC 8-K
Approved drugs (4)
- LYBALVIOLANZAPINE2021 · Prescription
- ARISTADA INITIO KITARIPIPRAZOLE LAUROXIL2018 · Prescription
- ARISTADAARIPIPRAZOLE LAUROXIL2015 · Prescription
- VIVITROLNALTREXONE2006 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $53 (+0% upside) · 17 analysts
- 2026-07-20StifelBuy
- 2026-07-13NeedhamBuy
- 2026-07-02MizuhoOutperform
- 2026-06-29Wells FargoOverweight
- 2026-06-29B of A SecuritiesNeutral → Underperform
- 2026-06-24NeedhamBuy
Competitors — Narcolepsy Type 1
Recent news
- 2026-07-21Alkermes plc (ALKS) Q4 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Alkermes plc (ALKS) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-15Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS) - Sahm
- 2026-07-15Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpace
- 2026-07-14Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Business Wire
- 2026-07-13Alkermes reports nine-month narcolepsy drug trial results - Investing.com UK
- 2026-07-13Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis - BioSpace
- 2026-07-13What's Going on With Alkermes Stock Monday? - Alkermes (NASDAQ:ALKS) - Benzinga
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.